Latest in News & Research
Isolated Nail Psoriasis Does Not Increase Risk for Metabolic Syndrome
Both metabolic syndrome components and related medical conditions seen at similar rates between patients with, without isolated nail psoriasis
Vitamin D Supplements Do Not Reduce Asthma Exacerbations Overall
Supplements reduce risk among children with low serum 25(OH)D and have beneficial effects in children with atopic dermatitis, allergic rhinitis
Thermal Images Differentiate Healed From Unhealed Wounds
Thermal images taken in home settings at week 0 can discriminate healed from unhealed leg venous ulcer wounds
Do Clinical Characteristics of Rosacea in Women Differ With Age?
Patients aged 45 years or older at diagnosis more likely to have serious persistent erythema and telangiectasia
How Do Lip Filler Products Differ in Terms of Outcomes?
No one product is superior for all categories; more of an increase seen in lip heig
Diversity Gaps Persist in Dermatology Workforce Pipeline
Students pursuing dermatology have lower odds of intending to care for underserved populations, practice in underserved areas
Update Shows Relatlimab Nivolumab Slows Advanced Melanoma
Progression-free survival prolonged with relatlimab nivolumab versus nivolumab alone for previously untreated advanced melanoma
Urban Dwelling Indigenous Young People Face Higher Burden of Skin Conditions
Incidence rates of atopic dermatitis and bacterial skin infections higher among urban-living Indigenous children and young people in high-income countries
Are Hyaluronic Acid Fillers With Mepivacaine, Lidocaine Equally Effective?
Mepivacaine found to be noninferior versus lidocaine for pain relief and bilateral wrinkle improvement
Can Vitamin D Supplementation Cut Incidence of Keratinocyte Cancer?
Researchers find no evidence that vitamin D supplementation reduces incidence of keratinocyte cancer
Subset of Stage I Melanoma Patients ID'd With Very Low Mortality
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes
Monkeypox Infection Rare in Children, Adolescents Younger Than 18
Monkeypox virus infection among <18s accounted for 0.3 percent of reported cases; most children were not hospitalized
Presymptomatic Transmission Seen With Monkeypox
Transmission detected up to a maximum of four days before onset of symptoms
Improvements Sustained With Continuing Apremilast in Psoriasis
Static Physician's Global Assessment response maintained for those continuing apremilast, receiving apremilast after placebo
Serum Dupilumab Levels Not Linked to Treatment Response in Eczema
Odds ratios for serum dupilumab levels at 16 weeks predicting long-term response and adverse events not significant
Psoriasis Not Tied to Myocardial Infarction in Patients With ESRD
Confounding variables, particularly comorbidities, impact association
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
Clinic Visits for Itch, Eczema Up for Seniors During Wildfire
Increase in adjusted rate of clinic visits for itch and atopic dermatitis seen during week with versus without wildfire among adults aged 65 years...
Return to ED Common for Hidradenitis Suppurativa Patients
17.2 percent of patients had at least one return emergency department visit within 30 days, while 2.4 percent had a dermatology visit
USPSTF: Evidence Still Lacking for Routine Skin Cancer Screening
Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults
Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma
Ruxolitinib Cream Results in Greater Repigmentation in Vitiligo
More patients receiving ruxolitinib have decrease of at least 75 percent from baseline in facial Vitiligo Area Scoring Index
Response-Adapted Treatment De-escalation Cost-Effective in Melanoma
Response-adapted de-escalation of immunotherapy yielded incremental net monetary benefit of $28,849 versus standard of care
24 of 1292